MacroGenics raises $110M following breast cancer data

Days after its shares more than doubled based on a Phase III breast cancer readout, MacroGenics Inc. (NASDAQ:MGNX) raised $110 million in a follow-on.

MacroGenics sold 5.5 million shares at $20, pricing at a 5% discount to Tuesday's close of $20.99. The company proposed the offering after market hours Tuesday, and priced later in the evening. MacroGenics climbed $0.30 to $21.29 on Wednesday...